

METAFACTENE PRO REPORT

CELL LINE: U87 MG


AIMS:

1. METAFACTENE TOXICITY
2. INFLUENCE OF METAFACTENE ON DRUG TOXICITY
3. TRANSFECTION OF siRNAs

Dr Massimo Nabissi Ph.D.
Department of Experimental Medicine and Public Health
Via Madonna delle Carceri 9
University of Camerino
62032 Camerino (MC)

Tel ++390737403312
Fax ++390737403325
E-mail: massimo.nabissi@unicam.it


INFLUENCE OF METAFACTENE ON CELL GROWTH



MTT assay on U87 Mg cells (1×10^5 /well) incubated with MEM or MEM + METAFACTENE PRO in a final volume of 150 μ l. Each bar represents the mean percentage of surviving cells \pm DS. Each treatment was in triplicate.

The result indicate no METAFACTENE (0.2-0.6 mL dose) influence on cell growth.



EFFECT OF METAFECTENE ON DRUG TOXICITY




MTT assay on U87 MG (1×10^5 /well) cells incubated up to 96 hours with different doses of BCNU or BCNU plus 0.6 ml METAFECTENE in a final volume of 150 ml. Each bar represents the mean percentage of surviving cells \pm DS. Each treatment was in triplicate.

The result indicates that METAFECTENE may be used in toxicity test, without influences on drug cytotoxicity effect.

TRANSFECTION OF siFLU IN U87 MG CELLS





MTT assay showing the effect of different doses (nM) of siFLU (Dharmacon, cod.D-001600-01-05) on U87 MG surviving. The results indicated that from 10 up to 50 nM of siFLU haven't effect on U87 viability.



siFlu 50 nM without
METAFACTENE

Semi-quantitative Western Blot





siGAPDH: Dharmacon cod. D-001140-01-05

Future direction

1. Transient transfection of GFP-plasmid in human primary glioma cells
2. Gene silencing in human urothelial cancer cells
3. Gene silencing in human brain cancer stem cells
4. Transient transfection of GFP-plasmid in human brain cancer stem cells